Health Catalyst (NASDAQ:HCAT) Posts Q1 Sales In Line With Estimates, Stock Soars
Healthcare software provider Health Catalyst (NASDAQ:HCAT) met Wall Street's revenue expectations in Q1 CY2025, with sales up 6.3% year on year to $79.41 million. On the other hand, next quarter's revenue guidance of $80.5 million was less impressive, coming in 3.1% below analysts' estimates. Its non-GAAP profit of $0.01 per share was in line with analysts' consensus estimates.
Is now the time to buy Health Catalyst? Find out in our full research report.
Health Catalyst (HCAT) Q1 CY2025 Highlights:
Revenue: $79.41 million vs analyst estimates of $79.21 million (6.3% year-on-year growth, in line)
Adjusted EPS: $0.01 vs analyst estimates of $0 (in line)
Adjusted EBITDA: $6.28 million vs analyst estimates of $4.15 million (7.9% margin, 51.3% beat)
The company reconfirmed its revenue guidance for the full year of $335 million at the midpoint
EBITDA guidance for the full year is $41 million at the midpoint, above analyst estimates of $39.59 million
Operating Margin: -25.4%, up from -30.5% in the same quarter last year
Free Cash Flow was -$5.05 million compared to -$8.36 million in the previous quarter
Market Capitalization: $278.7 million
'For the first quarter of 2025, I am pleased by our strong financial results, including total revenue of $79.4 million and Adjusted EBITDA of $6.3 million, with these results beating our quarterly guidance on each metric,' said Dan Burton, CEO of Health Catalyst.
Company Overview
Founded by healthcare professionals Tom Burton and Steve Barlow in 2008, Health Catalyst (NASDAQ:HCAT) provides data and analytics technology to healthcare organizations, enabling them to improve care and lower costs.
Sales Growth
A company's long-term sales performance can indicate its overall quality. Any business can put up a good quarter or two, but the best consistently grow over the long haul. Over the last three years, Health Catalyst grew its sales at a weak 7% compounded annual growth rate. This fell short of our benchmark for the software sector and is a rough starting point for our analysis.
Health Catalyst Quarterly Revenue
This quarter, Health Catalyst grew its revenue by 6.3% year on year, and its $79.41 million of revenue was in line with Wall Street's estimates. Company management is currently guiding for a 6.1% year-on-year increase in sales next quarter.
Looking further ahead, sell-side analysts expect revenue to grow 10.2% over the next 12 months, an acceleration versus the last three years. This projection is above average for the sector and indicates its newer products and services will spur better top-line performance.
Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) stock benefiting from the rise of AI. Click here to access our free report one of our favorites growth stories.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Times
14 minutes ago
- New York Times
‘Golden Share' in U.S. Steel Gives Trump Extraordinary Control
To save its takeover of U.S. Steel, Japan's Nippon Steel agreed to an unusual arrangement, granting the White House a 'golden share' that gives the government an extraordinary amount of influence over a U.S. company. New details of the agreement show that the structure would give President Trump and his successors a permanent stake in U.S. Steel, significant sway over its board and veto power over a wide array of company actions, an arrangement that could change the nature of foreign investment in the United States. The terms of the arrangement were hammered out in meetings that went late into the night on Wednesday and Thursday, according to two people familiar with the details. Representatives from Nippon Steel — which had been trying to acquire the struggling U.S. Steel since December 2023, but had been blocked by the Biden administration over national security concerns — came around to Mr. Trump's desire to take a stake that would give the U.S. government significant control over the company's actions. Nippon had argued that this influence should expire — perhaps after three or four years, the duration of the Trump administration. But in the meetings, which were held at the Commerce Department, Trump officials led by Commerce Secretary Howard Lutnick insisted that the golden share should last in perpetuity, the two people said. Under the terms of the national security pact, which the companies said they signed Friday, the U.S. government would retain a single share of preferred stock, called class G — as in gold. And U.S. Steel's charter will list nearly a dozen activities the company cannot undertake without the approval of the American president or someone he designates in his stead. Want all of The Times? Subscribe.
Yahoo
17 minutes ago
- Yahoo
5 of the Richest People in Real Estate
Real estate can become a strategic investment option if you know what you're doing and are willing to put in some work. While you might not make several million dollars, it can be another way to boost your bank account and wealth. Read Next: Find Out: Speaking of wealth, real estate has paid off extremely well for some investors and managers around the U.S. and beyond. Here's a look at five of the richest people in real estate. Also see what the 10 richest billionaires did with their first $1 million. Total net worth: $18.7 billion You may not be familiar with Kushal Pal Singh, but he's one of the richest billionaires in the real estate industry. He's the chairman emeritus of a leading real estate company in India called DLF. According to Forbes, the company is the biggest listed property firm by market cap in India. Check Out: Total net worth: $19.7 billion Harry Triguboff is the owner of Meriton, an apartment tower development company in Australia. He's a billionaire real estate developer — and one of the richest people in Australia. According to Forbes, he has built over 79,000 apartments and was a trailblazer, being one of the first developers see potential in apartments rather than single-family homes. Late last year, Medium called him 'the GOAT' of real estate in Australia. Total net worth: $18.9 billion Donald Bren is a big name in real estate in America. He's the chairman of Irvine Company, which, according to Sunrise Capital, has more than 120 million square feet of office space, apartments and malls across California. Per Forbes, he also owns the MetLife Building in New York. Total net worth: $18.4 billion Stephen Ross may have come from humble beginnings, but he's now one of the richest names in real estate. Ross is the CEO and chairman of Related Ross and the owner of the Miami Dolphins. Due to his real estate work, he's especially well known in Florida. According to the company's website, it has many types of properties, including office space, hotels and city centers. Total net worth: $13.2 billion Until 2015, Peter Woo was the chairman of Wheelock & Co., a property developer, and the subsidiary Wharf Holdings, per Forbes. In addition to real estate, the companies are involved in retailing and telecommunications. Editor's note: Net worth figures were sourced from Forbes. More From GOBankingRates How Much Money Is Needed To Be Considered Middle Class in Every State? This article originally appeared on 5 of the Richest People in Real Estate Sign in to access your portfolio
Wall Street Journal
22 minutes ago
- Wall Street Journal
Leonard Lauder, Who Turned His Mother's Beauty Business Into a Global Empire, Dies at 92
Leonard Lauder, the eldest son of beauty pioneer Estée Lauder who grew up typing invoices for the family business he would later transform into a global empire, died Saturday at the age of 92, the company said. In five decades at Estée Lauder, including a 17-year tenure as chief executive, Lauder secured prime spots in every major U.S. department store and built a portfolio of beauty's biggest names, including Bobbi Brown, Aveda and MAC.
